Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Mirum Pharmaceuticals Inc MIRM

Healthcare Biotechnology
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with... see more

Current News (NDAQ:MIRM)

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 12 days ago

Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum

Business Wire 12 days ago

Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Business Wire January 7, 2026

Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX

Business Wire December 19, 2025

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 10, 2025

Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

Business Wire December 8, 2025

Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome

Business Wire December 1, 2025

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Business Wire November 25, 2025

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 10, 2025
View More News ››

Opinion & Analysis (NDAQ:MIRM)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:MIRM)

$iMIN making moves in Ethereum Crypto !! 🚀🚀🚀🚀🚀

iMining Launches Fractional Staking to Enable Retail Investors to Participate in Ethereum 2.0's Proof-Of-Stake Mining Vancouver...
Saaaa1 - May 6, 2021

Patient Virtue

This is a space and stock to watch... interesting times ahead
deMaverick - January 8, 2021
View more Bullboard ››

Electrum Discovery Corp.

Electrum Discovery Corp.

Electrum Discovery Corp. engages in the acquisition and exploration of mineral properties in the natural resource sector in ...
View More »

Podcasts